- Home
- LQDT vs CVAC Comparison
LQDT vs CVAC Comparison
Compare LQDT & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LQDT | CVAC |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.6M | 1.1B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LQDT | CVAC |
|---|---|---|
| Price | $31.15 | $4.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $40.00 | $6.83 |
| AVG Volume (30 Days) | 170.3K | ★ 1.7M |
| Earning Date | 02-05-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.09 | ★ 94.02 |
| EPS | 0.87 | ★ 0.94 |
| Revenue | ★ $476,669,000.00 | $83,000,117.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.71 |
| P/E Ratio | $35.80 | ★ $4.59 |
| Revenue Growth | ★ 31.20 | N/A |
| 52 Week Low | $21.67 | $2.48 |
| 52 Week High | $39.72 | $5.72 |
Technical Indicators
Market Signals| Indicator | LQDT | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 62.94 | 31.39 |
| Support Level | $30.51 | $4.00 |
| Resistance Level | $32.15 | $4.36 |
| Average True Range (ATR) | 0.69 | 0.16 |
| MACD | -0.28 | -0.06 |
| Stochastic Oscillator | 45.42 | 22.51 |
Price Performance
Historical ComparisonAbout LQDT Liquidity Services Inc.
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.